Loading…
Reported covered position: Assistant to the Chief of Staff, Senator Ben Nelson (2005-2006)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 475, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019 S. 1437, Drug-price Transparency in Communications (DTC) Act Medicaid, Medicare, Medicare Part B, Medicaid Rebate Cap, 340B reforms Medicare Part D, Part D inflationary rebate, International pricing index, Drug Pricing and Center for Medicare & Medicaid Demonstrations.
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
MERCK & CO INC via MERCK & CO, INC.
2019 · first_quarter · 1A
340B Reforms, Drug pricing, Anti-microbial Resistance, Hearing Prep, AMR,Drug Pricing; (General Pharmaceutical issues (transparency, formulary design, prescription drug coverage, Patent Thickets, W&M Markup Transparency, Biosimiliars
Medicaid, Medicare, Medicare Part B, Medicaid Rebate Cap, 340B reforms Medicare Part D, Drug Pricing
Source: Senate LDA
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 475, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019 S. 1437, Drug-price Transparency in Communications (DTC) Act Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid Innovation; Medicaid Part D.
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 475, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019 S. 1437, Drug-price Transparency in Communications (DTC) Act Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid Innovation; Medicaid Part D.
More Efficient Tools to Realize Information for Consumers Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Affordable Care Act; Vaccines; Women's Health; Average Manufacturer Price (AMP) CAP repeal; Ebola; Antibiotics.
More Efficient Tools to Realize Information for Consumers Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 340B Reforms, Drug pricing, Anti-microbial Resistance, General Pharmaceutical issues transparency, formulary design, prescription drug coverage, Biosimiliars, Cost and value of medicines, Maternal Health, Affordable Care Act, Importation, Vaccines.
More Efficient Tools to Realize Information for Consumers Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Affordable Care Act; Vaccines; Women's Health; Average Manufacturer Price (AMP) CAP repeal; Ebola; Antibiotics.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 340B Reforms, Drug pricing, Anti-microbial Resistance, General Pharmaceutical issues transparency, formulary design, prescription drug coverage, Biosimiliars, Cost and value of medicines, Maternal Health, Affordable Care Act, Importation, Vaccines.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Affordable Care Act; Vaccines; Women's Health; Average Manufacturer Price (AMP) CAP repeal; Ebola; Antibiotics.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Affordable Care Act; Vaccines; Women's Health; Average Manufacturer Price (AMP) CAP repeal; Ebola; Antibiotics.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Affordable Care Act; Vaccines; Women's Health; Average Manufacturer Price (AMP) CAP repeal; Ebola; Antibiotics.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Affordable Care Act; Vaccines; Women's Health; Average Manufacturer Price (AMP) CAP repeal; Ebola; Antibiotics.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 340B Reforms, Drug pricing, Anti-microbial Resistance, General Pharmaceutical issues transparency, formulary design, prescription drug coverage, Biosimiliars, Cost and value of medicines, Maternal Health, Affordable Care Act, Importation, Vaccines.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Affordable Care Act; Vaccines; Women's Health; Average Manufacturer Price (AMP) CAP repeal; Ebola; Antibiotics.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Affordable Care Act; Vaccines; Women's Health; Average Manufacturer Price (AMP) CAP repeal; Ebola; Antibiotics.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 340B Reforms, Drug pricing, Anti-microbial Resistance, General Pharmaceutical issues transparency, formulary design, prescription drug coverage, Biosimiliars, Cost and value of medicines, Maternal Health, Affordable Care Act, Importation, Vaccines.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Affordable Care Act; Vaccines; Women's Health; Average Manufacturer Price (AMP) CAP repeal; Ebola; Antibiotics.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 340B Reforms, Drug pricing, Anti-microbial Resistance, General Pharmaceutical issues transparency, formulary design, prescription drug coverage, Biosimiliars, Cost and value of medicines, Maternal Health, Affordable Care Act, Importation, Vaccines.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Affordable Care Act; Vaccines; Women's Health; Average Manufacturer Price (AMP) CAP repeal; Ebola; Antibiotics.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Affordable Care Act; Vaccines; Women's Health; Average Manufacturer Price (AMP) CAP repeal; Ebola; Antibiotics.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 340B Reforms, Drug pricing, Anti-microbial Resistance, General Pharmaceutical issues transparency, formulary design, prescription drug coverage, Biosimiliars, Cost and value of medicines, Maternal Health, Affordable Care Act, Importation, Vaccines.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Affordable Care Act; Vaccines; Women's Health; Average Manufacturer Price (AMP) CAP repeal; Ebola; Antibiotics.
Drug-price Transparency in Communications (DTC) Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 475, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019 S. 1437, Drug-price Transparency in Communications (DTC) Act Medicaid, Medicare, Medicare Part B, Medicaid Rebate Cap, 340B reforms Medicare Part D, Part D inflationary rebate, International pricing index, Drug Pricing and Center for Medicare & Medicaid Demonstrations.
Drug-price Transparency in Communications (DTC) Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 475, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019 S. 1437, Drug-price Transparency in Communications (DTC) Act Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid Innovation; Medicaid Part D.
Drug-price Transparency in Communications (DTC) Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 475, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019 S. 1437, Drug-price Transparency in Communications (DTC) Act Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid Innovation; Medicaid Part D.
Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Affordable Care Act; Vaccines; Women's Health; Average Manufacturer Price (AMP) CAP repeal; Ebola; Antibiotics.
Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 340B Reforms, Drug pricing, Anti-microbial Resistance, General Pharmaceutical issues transparency, formulary design, prescription drug coverage, Biosimiliars, Cost and value of medicines, Maternal Health, Affordable Care Act, Importation, Vaccines.
Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Affordable Care Act; Vaccines; Women's Health; Average Manufacturer Price (AMP) CAP repeal; Ebola; Antibiotics.
Prescription Drug Pricing Reduction Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 340B Reforms, Drug pricing, Anti-microbial Resistance, General Pharmaceutical issues transparency, formulary design, prescription drug coverage, Biosimiliars, Cost and value of medicines, Maternal Health, Affordable Care Act, Importation, Vaccines.
Prescription Drug Pricing Reduction Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Affordable Care Act; Vaccines; Women's Health; Average Manufacturer Price (AMP) CAP repeal; Ebola; Antibiotics.
Prescription Drug Pricing Reduction Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Affordable Care Act; Vaccines; Women's Health; Average Manufacturer Price (AMP) CAP repeal; Ebola; Antibiotics.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 475, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019 S. 1437, Drug-price Transparency in Communications (DTC) Act Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid Innovation; Medicaid Part D.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 475, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019 S. 1437, Drug-price Transparency in Communications (DTC) Act Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid Innovation; Medicaid Part D.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 475, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019 S. 1437, Drug-price Transparency in Communications (DTC) Act Medicaid, Medicare, Medicare Part B, Medicaid Rebate Cap, 340B reforms Medicare Part D, Part D inflationary rebate, International pricing index, Drug Pricing and Center for Medicare & Medicaid Demonstrations.
Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 475, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019 S. 1437, Drug-price Transparency in Communications (DTC) Act Medicaid, Medicare, Medicare Part B, Medicaid Rebate Cap, 340B reforms Medicare Part D, Part D inflationary rebate, International pricing index, Drug Pricing and Center for Medicare & Medicaid Demonstrations.
Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 475, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019 S. 1437, Drug-price Transparency in Communications (DTC) Act Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid Innovation; Medicaid Part D.
Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 475, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019 S. 1437, Drug-price Transparency in Communications (DTC) Act Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid Innovation; Medicaid Part D.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3358 Department of Labor, Health and Human Services Education and Related Agencies Appropriations
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3358 Department of Labor, Health and Human Services Education and Related Agencies Appropriations
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 1 (Tax Cuts and Jobs Act)
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
H.R. 2028 (continuing resolution to fund the federal government); S. Con. Res. 3 (Senate Budget Resolution 2017) - prescription drug policies. FY2017/FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2017/FY2018, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2017/FY2018, Department of Defense Appropriations; Tricare formulary, reimbursement and vial size issues.
H.R. 2028 (continuing resolution to fund the federal government); S. Con. Res. 3 (Senate Budget Resolution 2017) - prescription drug policies. FY2017/FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2017/FY2018, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2017/FY2018, Department of Defense Appropriations; Tricare formulary, reimbursement and vial size issues.
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), H.R. 5122 (Centers for Medicare and Medicaid Innovation Part B demo), Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education); Medicaid (no specific bill); Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs; Antibiotics/stewardship; Cost and value of prescription drugs; Vaccines for Children Program, Part B Drug Demonstration Proposed Rule; Medicare access to DXA services; Hospital Outpatient Prospective Payment proposed rule (CMS).
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), H.R. 5122 (Centers for Medicare and Medicaid Innovation Part B demo), Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education); Medicaid (no specific bill); Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs; Antibiotics/stewardship; Cost and value of prescription drugs; Vaccines for Children Program, Part B Drug Demonstration Proposed Rule; Medicare access to DXA services; Hospital Outpatient Prospective Payment proposed rule (CMS).
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Affordable and Safe Prescription Drug Importation Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Affordable and Safe Prescription Drug Importation Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Affordable and Safe Prescription Drug Importation Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), Hepatitis C (general education; no specific bill), Vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), Implementation of P.L.114-255 - 21st Century Cures Act, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Affordable and Safe Prescription Drug Importation Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), Hepatitis C (general education; no specific bill), Vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), Implementation of P.L.114-255 - 21st Century Cures Act, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), Hepatitis C (general education; no specific bill), Vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), Implementation of P.L.114-255 - 21st Century Cures Act, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), Hepatitis C (general education; no specific bill), Vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), Implementation of P.L.114-255 - 21st Century Cures Act, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 2028 (continuing resolution to fund the federal government); S. Con. Res. 3 (Senate Budget Resolution 2017) - prescription drug policies. FY2017/FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2017/FY2018, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2017/FY2018, Department of Defense Appropriations; Tricare formulary, reimbursement and vial size issues.
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 2028 (continuing resolution to fund the federal government); S. Con. Res. 3 (Senate Budget Resolution 2017) - prescription drug policies. FY2017/FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2017/FY2018, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2017/FY2018, Department of Defense Appropriations; Tricare formulary, reimbursement and vial size issues.
Further Continuing and Security Assistance Appropriations Act, 2017
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 2028 (continuing resolution to fund the federal government)
Strengthening Public Health Emergency Response Act of 2016
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education), shingles vaccine policies (general education), antimicrobial resistance (general education and DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), Senate Innovation Project (no bill number), cost and value of medicines (no specific bill), Strengthening Public Health Emergncy Response Act (H.R. 3299), priority review voucher and medical countermeasures (general education), women's health (general education), insurance benefit design and value-based contracting (general education), general pharmaceutical issues
Preserving Access to Orphan Drugs Act of 2015
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Comprehensive tax reform (no specific bill), House Republican tax blueprint, international tax proposals (no specific bill), orphan drug legislation (HR 3678)
Preserving Access to Orphan Drugs Act of 2015
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Comprehensive tax reform (no specific bill), House Republican tax blueprint, international tax proposals (no specific bill), orphan drug legislation (HR 3678)
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education), shingles vaccine policies (general education), antimicrobial resistance (general education and DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), Senate Innovation Project (no bill number), cost and value of medicines (no specific bill), priority review voucher, biodefense and medical countermeasures (general education), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, S. 3056 (CREATES Act), risk evaluation and mitigation strategies (general education), general pharmaceutical issues
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education), shingles vaccine policies (general education), antimicrobial resistance (general education and DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), Senate Innovation Project (no bill number), cost and value of medicines (no specific bill), Strengthening Public Health Emergncy Response Act (H.R. 3299), priority review voucher and medical countermeasures (general education), women's health (general education), insurance benefit design and value-based contracting (general education), general pharmaceutical issues
To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), H.R. 5122 (Centers for Medicare and Medicaid Innovation Part B demo), Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education); Medicaid (no specific bill)
To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), H.R. 5122 (Centers for Medicare and Medicaid Innovation Part B demo), Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education); Medicaid (no specific bill)
To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), H.R. 5122 (Centers for Medicare and Medicaid Innovation demo), Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education, no specific bill); Medicaid (no specific bill)
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), 21st Century Cures (H.R.6), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage)
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education), shingles vaccine policies (general education), antimicrobial resistance (general education and DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), Senate Innovation Project (no bill number), cost and value of medicines (no specific bill), Strengthening Public Health Emergncy Response Act (H.R. 3299), priority review voucher and medical countermeasures (general education), women's health (general education), insurance benefit design and value-based contracting (general education), general pharmaceutical issues
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education), shingles vaccine policies (general education), antimicrobial resistance (general education and DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), Senate Innovation Project (no bill number), cost and value of medicines (no specific bill), priority review voucher, biodefense and medical countermeasures (general education), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, S. 3056 (CREATES Act), risk evaluation and mitigation strategies (general education), general pharmaceutical issues
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education), shingles vaccine policies (general education), antimicrobial resistance (general education and DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), Senate Innovation Project (no bill number), cost and value of medicines (no specific bill), priority review voucher, biodefense and medical countermeasures (general education), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, S. 3056 (CREATES Act), risk evaluation and mitigation strategies (general education), general pharmaceutical issues
Tax Reform, Appropriations
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MERCK & CO INC via MERCK & CO, INC.
2019 · fourth_quarter · 4A
Issues relating to, Intellectual Property; US-Mexico-Canada Agreement; US-China trade; Patents/IP; Market exclusivity.
Tax Reform, Generally
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 475, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019 S. 1437, Drug-price Transparency in Communications (DTC) Act Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid Innovation; Medicaid Part D.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Affordable Care Act; Vaccines; Women's Health; Average Manufacturer Price (AMP) CAP repeal; Ebola; Antibiotics.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MERCK & CO INC via MERCK & CO, INC.
2019 · fourth_quarter · Q4
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Affordable Care Act; Vaccines; Women's Health; Average Manufacturer Price (AMP) CAP repeal; Ebola; Antibiotics.
Tax Reform, Generally
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 475, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019 S. 1437, Drug-price Transparency in Communications (DTC) Act Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid Innovation; Medicaid Part D.
Issues relating to, Intellectual Property; US-Mexico-Canada Agreement; US-China trade; Patents/IP; Market exclusivity.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MERCK & CO INC via MERCK & CO, INC.
2019 · third_quarter · Q3
Intellectual Property, US-Mexico-Canada Agreement and US-China trade
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 475, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019 S. 1437, Drug-price Transparency in Communications (DTC) Act Medicaid, Medicare, Medicare Part B, Medicaid Rebate Cap, 340B reforms Medicare Part D, Part D inflationary rebate, International pricing index, Drug Pricing and Center for Medicare & Medicaid Demonstrations.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 340B Reforms, Drug pricing, Anti-microbial Resistance, General Pharmaceutical issues transparency, formulary design, prescription drug coverage, Biosimiliars, Cost and value of medicines, Maternal Health, Affordable Care Act, Importation, Vaccines.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MERCK & CO INC via MERCK & CO, INC.
2019 · first_quarter · Q1
Medicaid, Medicare, Medicare Part B, Medicaid Rebate Cap, 340B reforms Medicare Part D, Drug Pricing
Tax Reform, Appropriations
340B Reforms, Drug pricing, Anti-microbial Resistance, Hearing Prep, AMR,Drug Pricing; (General Pharmaceutical issues (transparency, formulary design, prescription drug coverage, Patent Thickets, W&M Markup Transparency, Biosimiliars
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MERCK & CO INC via MERCK & CO, INC.
2018 · fourth_quarter · Q4
Issues related to Animal Drug User fee Act Reauthorization with conditional approval, Animal health
Medicare Part D (general education, no specific bill); Medicare Part B (general education, reimbursement); Medicaid (no specific bill); Antibiotics/stewardship; Center for Medicare and Medicaid Innovation (CMMI) demonstration; Drug pricing
340B reforms (no specific bill); Hepatitis C (general education, no specific bill); Vaccine policies (general education, first dollar coverage); antimicrobial resistance (general education); biosimilars (no specific bill); cost and value of medicines (no specific bill); women's health (general education); Affordable Care Act; general pharmaceutical issues (transparency, formulary design, prescription drug coverage); 21st Century Cures Act; Direct to Consumer advertising; Drug pricing
MERCK & CO INC via MERCK & CO, INC.
2018 · third_quarter · Q3
340B (no specific bill); Hepatitis C (general education, no specific bill); Vaccine policies (general education, first dollar coverage, preventative services); antimicrobial resistance (general education); biosimilars (no specific bill); importation; cost and value of medicines (no specific bill); women's health (general education); Affordable Care Act; general pharmaceutical issues (transparency, formulary design, prescription drug coverage); 21st Century Cures Act; DTC; Drug pricing
Medicare Part D (general education, no specific bill); LIS Co-Pays (general education, no specific bill); Independent Payment Advisory Board (general education, no specific bill); Medicare Part B (general education, reimbursement); Medicaid (no specific bill); Antibiotics/stewardship; Center for Medicare and Medicaid Innovation (CMMI) demonstration; Drug pricing
MERCK & CO INC via MERCK & CO, INC.
2018 · second_quarter · Q2
Medicare Part D (general education, no specific bill); LIS Co-Pays (general education, no specific bill); Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education, reimbursement); Medicaid (no specific bill); Antibiotics/stewardship; Center for Medicare and Medicaid Innovation (CMMI) demonstration; Drug pricing
Issues related to Animal Drug User fee Act Reauthorization with conditional approval, Animal health
H.R. 3358 Department of Labor, Health and Human Services Education and Related Agencies Appropriations
MERCK & CO INC via MERCK & CO, INC.
2018 · first_quarter · Q1
H.R. 3358 Department of Labor, Health and Human Services Education and Related Agencies Appropriations
Medicare Part D (general education, no specific bill); LIS Co-Pays (general education, no specific bill); Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education, reimbursement); Medicaid (no specific bill); Antibiotics/stewardship; Center for Medicare and Medicaid Innovation (CMMI) demonstration; Drug pricing
340B (no specific bill), Hepatitis C (general education; no specific bill), Vaccine policies (general education; first dollar coverage; preventative services), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), PAHPA (Pandemic and All Hazards Preparedness Act); Drug pricing
MERCK & CO INC via MERCK & CO, INC.
2017 · third_quarter · 3A
Comprehensive tax reform (no specific bill), House Republican tax blueprint, international tax proposals (no specific bill).
FY2017/FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2017/FY2018, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2017/FY2018, Department of Defense Appropriations; TRICARE formulary and reimbursement issues.
340B (no specific bill), Hepatitis C (general education; no specific bill), Vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), Implementation of P.L.114-255 - 21st Century Cures Act, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
MERCK & CO INC via MERCK & CO, INC.
2017 · fourth_quarter · Q4
340B (no specific bill), Hepatitis C (general education; no specific bill), Vaccine policies (general education; first dollar coverage; preventative services), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), Implementation of P.L.114-255 - 21st Century Cures Act; PAHPA (Pandemic and All Hazards Preparedness Act)
Medicare Part D (general education, no specific bill); LIS Co-Pays (general education, no specific bill); Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education); Medicaid (no specific bill); Antibiotics/stewardship; Hospital Outpatient Prospective Payment proposed rule (CMS); Center for Medicare and Medicaid Innovation (CMMI) demonstration
MERCK & CO INC via MERCK & CO, INC.
2017 · third_quarter · Q3
Comprehensive tax reform (no specific bill), House Republican tax blueprint, international tax proposals (no specific bill).
Medicare Part D (general education, no specific bill); LIS Co-Pays (general education, no specific bill); Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education); Medicaid (no specific bill); Antibiotics/stewardship; Vaccines for Children Fund; Hospital Outpatient Prospective Payment proposed rule (CMS); Center for Medicare and Medicaid Innovation (CMMI) demonstration
FY2017/FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2017/FY2018, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2017/FY2018, Department of Defense Appropriations; TRICARE formulary and reimbursement issues.
MERCK & CO INC via MERCK & CO, INC.
2017 · first_quarter · 1A
Comprehensive tax reform (no specific bill), House Republican tax blueprint, international tax proposals (no specific bill).
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
MERCK & CO INC via MERCK & CO, INC.
2017 · first_quarter · Q1
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Comprehensive tax reform (no specific bill), House Republican tax blueprint, international tax proposals (no specific bill).
MERCK & CO INC via MERCK & CO, INC.
2016 · fourth_quarter · Q4
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), H.R. 5122 (Centers for Medicare and Medicaid Innovation Part B demo), Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education); Medicaid (no specific bill)
H.R. 2028 (continuing resolution to fund the federal government)
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), 21st Century Cures (H.R.6), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage)
MERCK & CO INC via MERCK & CO, INC.
2016 · third_quarter · Q3
Comprehensive tax reform (no specific bill), House Republican tax blueprint, international tax proposals (no specific bill), orphan drug legislation (HR 3678)
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), H.R. 5122 (Centers for Medicare and Medicaid Innovation Part B demo), Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education); Medicaid (no specific bill)
Animal health vaccines, FMD vaccine bank, USDA rule for categorical exclusions for animal health vaccines, FDA guidance 209-213, FDA rule regarding species-specific antibiotics data collection, Animal Drug User Fee Act
MERCK & CO INC via MERCK & CO, INC.
2016 · second_quarter · Q2
Trans-Pacific Partnership, data exclusivity for biologics, United Nations high level panel
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education), shingles vaccine policies (general education), antimicrobial resistance (general education and DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), Senate Innovation Project (no bill number), cost and value of medicines (no specific bill), Strengthening Public Health Emergncy Response Act (H.R. 3299), priority review voucher and medical countermeasures (general education), women's health (general education), insurance benefit design and value-based contracting (general education), general pharmaceutical issues
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FY2017/FY2018, Department of Labor, Health and Human Services Education and Related Agencies Appropriations; FY2017/FY2018, Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations
Issues related to Animal Drug User fee Act Reauthorization with conditional approval, Animal health
Intellectual Property (general education, no specific bill); NAFTA
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Tax reform
340B (no specific bill), Hepatitis C (general education; no specific bill), Vaccine policies (general education; first dollar coverage; preventative services), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), PAHPA (Pandemic and All Hazards Preparedness Act of 2018); Drug pricing; Opiods
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Medicare Part D (general education, no specific bill); LIS Co-Pays (general education, no specific bill); Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education); Medicaid (no specific bill); Antibiotics/stewardship; Vaccines for Children Fund; Hospital Outpatient Prospective Payment proposed rule (CMS); Center for Medicare and Medicaid Innovation (CMMI) demonstration
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
H.R. 1 (Tax Cuts and Jobs Act)
NAFTA; KORUS
Budget Appropriations
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
340B (no specific bill), Hepatitis C (general education; no specific bill), Vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), Implementation of P.L.114-255 - 21st Century Cures Act, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), H.R. 5122 (Centers for Medicare and Medicaid Innovation Part B demo), Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education); Medicaid (no specific bill); Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs; Antibiotics/stewardship; Cost and value of prescription drugs; Vaccines for Children Program, Part B Drug Demonstration Proposed Rule; Medicare access to DXA services; Hospital Outpatient Prospective Payment proposed rule (CMS).
H.R. 2028 (continuing resolution to fund the federal government); S. Con. Res. 3 (Senate Budget Resolution 2017) - prescription drug policies. FY2017/FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2017/FY2018, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2017/FY2018, Department of Defense Appropriations; Tricare formulary, reimbursement and vial size issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), H.R. 5122 (Centers for Medicare and Medicaid Innovation Part B demo), Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education); Medicaid (no specific bill); Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs; Antibiotics/stewardship; Cost and value of prescription drugs; Vaccines for Children Program, Part B Drug Demonstration Proposed Rule; Medicare access to DXA services; Hospital Outpatient Prospective Payment proposed rule (CMS).
H.R. 2028 (continuing resolution to fund the federal government); S. Con. Res. 3 (Senate Budget Resolution 2017) - prescription drug policies. FY2017/FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2017/FY2018, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2017/FY2018, Department of Defense Appropriations; Tricare formulary, reimbursement and vial size issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Comprehensive tax reform (no specific bill), House Republican tax blueprint, international tax proposals (no specific bill), orphan drug legislation (HR 3678)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Patent settlements/pay for delay (general education)
Trans-Pacific Partnership, data exclusivity for biologics
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education), shingles vaccine policies (general education), antimicrobial resistance (general education and DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), Senate Innovation Project (no bill number), cost and value of medicines (no specific bill), priority review voucher, biodefense and medical countermeasures (general education), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, S. 3056 (CREATES Act), risk evaluation and mitigation strategies (general education), general pharmaceutical issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), H.R. 5122 (Centers for Medicare and Medicaid Innovation demo), Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education, no specific bill); Medicaid (no specific bill)
FY17 Labor HHS Appropriations bills, FY17 Agriculture Appropriations bills, vial size
Filing targets: HOUSE OF REPRESENTATIVES, SENATE